

INTERNATIONAL SYMPOSIUM ON NUCLEAR MEDICINE
SCIENTIFIC PROGRAM March 27th, 2026

8.00-8.30	Registration	
Session 1: General Nuclear Medicine		
8.30-8.50	SPECT/CT for Assessment of Axillary Lymph Node Status in Breast Cancer after neoadjuvant Therapy: Sentinel LN Biopsy & MARI Tecnique	Pavel Krzhivitskiy, Russian Federation
8.50-9.10	Semi-Quantitative Grading of Esophageal Dysfunction in Patients with Scleroderma	Qaisar Siraj, Pakistan
9.10-9.30	Bone Scintigraphy in Osteosarcoma	Nevena Manevska, North Macedonia
9.30-9.50	How to confirm the diagnosis of cardiac amyloidosis using the nuclear medicine method? Reliability, dilemmas, and pitfalls	Dragana Šobić Šaranović, Serbia
9.50-10.10	The Role of Ventilation/Perfusion Tomography-V/P SPECT in detection of Cardiopulmonaly Diseases	Amela Begić, Bosnia and Herzegovina
10.10-10.30	Sensitivity, Specificity and Overall Accuracy of 99mTc-MIBI Scintigraphy in Detection of Thyroid Malignancy	Marko Kojić, Serbia
10.30-10.50	The Role of Nuclear medicine Imaging in Assessment of Prostate Cancer Dissemination	Ana Jakovljević, Serbia
10.50-11.10	Castration-resistant Prostate Cancer - Integrating Nuclear Medicine and Oncology perspective in clinical practice Sponsored by NoVARTIS	Maja Popović & Emil Matovina, Serbia
11.10-11.30	Discussion	
11.30-11.45	COFFEEE BREAK	
	Session 2: Nuclear Medicine – Metabolic Imaging	
11.45-12.05	Role of PET-CT in the Multidisciplinary Management of Lung Cancer	Sabina Dizdarevic, UK
12.05-12.25	PET-CT Imaging in NETs	Gopinath Gnanasegaran, UK
12.25-12.45	PET Molecular Imaging in Alzheimer’s disease	Javier Arbizu, Spain
12.45-13.05	FDG in CUP	Raluca Mititelu, Romania
13.05-13.15	Discussion	
13.15-13.45	LUNCH	
Session 3: Nuclear Medicine - Therapy		
13.45-14.05	Tandem RLT: Redefining radioligand Therapy Boundaries	Masha Maharaj, South Africa
14.05-14.25	Several Aspects of Clinical Trials for targeted radiotracers: A Review of the Russian Experience	Viacheslav Sukhov, Russian Federation
14.25-14.45	Ac-225 PSMA and Lu-177 PSMA: Comparison of Capabilities and Disadvantages	Valerij Krylov, Russian Federation
14.45-15.05	Current Status and Future Perspectives of Peptide Receptor Radionuclide Therapy in NET	Aleksandar Filimonov, Russian Federation
15.05-15.25	Navigating Pitfalls of FAPI PET/CT Interpretation and Insight into FAPI Theranostics	Akram Al-Ibraheem, Jordan
15.25-15.45	From Tradition to Personalization: Postoperative Assessment of Papillary Thyroid Cancer	Marina Popović Krneta, Serbia
15.45-16.05	Radioiodine Therapy in Differentiated Thyroid Cancer: Where We Were, Where We Are, and Where We’re Going	Jasna Mihailović, Serbia
16.05 -16.20	Discussion	
16.20-17.50	Session 4: Poster Presentations	
17.50-18.20	CME Test	
18.20-18.30	Closing of the Symposium	